Stock Intuition & Predictions

[$hellKing]

Source : Press Release
Date : 2011-09-12
Companies : Protect Pharmaceuticals, Inc.

Protect Pharma (OTCBB:PRTT) Develops Revolutionary Drug Platforms

PRINCETON, NEW JERSEY, September 12, 2011-- Protect Pharma Corp (OTCBB:PRTT) is a Pharmaceutical company with innovative drug delievery technology and promising pipeline.Unlike other drug delivery companies like Alkermes Inc. (NASDAQ: ALKS) and Apricus Bioscience Inc. (NASDAQ: APRI), the company’s technology offers increased clinical efficacy via novel delivery that enables a better therapeutic profile with lower doses.

Key Highlights

Unique Drug Delivery Platform. Protect Pharma has developed two drug delivery platforms that have very unique mechanisms of action.
Rock Solid Business Model. Protect Pharma has developed a rock solid business model designed to minimize uncertainty, reduce development costs, and reduce time to market.
An Undervalued Opportunity. Protect Pharma appears to be significantly undervalued given its potential, unique technology, and promising development pipeline.

Unique Drug Delivery Platform

Protect Pharma has developed two unique drug delivery platforms, called ProRet™ and ProProof™. ProRet™ is a unique gastro-retentive delivery platform designed to significantly prolong the absorption window for a number of key drugs. Meanwhile, ProProof™ is an abuse-deterrant formulation that limits the abuse potential of drugs that are prone to abuse.

These layered platforms enable more than one drug work at the same time, while increasing efficacy by prolonging the absorption window. Ultimately, the company hopes to apply the platform to a number of different gastro and pain-related indications.

Rock Solid Business Model

Protect Pharma’s unique business model enables it to develop innovative new products using existing pharmaceuticals to address unmet medical needs. This model minimizes discovery uncertainty, reduces the cost of development and reduces the time to market because of well defined FDA regulatory pathway (505 b(2)). Backed with a unique delivery technology, the company has already begun developing two drugs – PRTT-200 and PRTT-300. In addition, Protect has two first in class projects- PRTT-210 Once daily gastro-retentive combination drug. PRTT-310 is both abuse deterrent and once daily opioid combination product. No such combination products been approved.

PRTT-200 is a gastro-retentive once daily Pregabalin to treat diabetic neuropathic pain, fibromyalgia, epilepsy and neuralgia. With market potential estimated to be about $5 billion, the drug will directly compete against Pfizer’s Lyrica© and Eli Lilly’s Cymbalta©. Meanwhile, PRTT-300 is a once daily efficacy-enhanced, abuse deterrent that addresses a $6 billion market.

PRTT-210 is once daily gastro-retentive Pregabalin + Opioid combination while the PRTT-310 is abuse deterrent and once daily Opioid + Acetaminophen combination addressing a total $ 11 billion market opprtunities

An Undervalued Opportunity

Currently, Protect Pharma trades with a market capitalization of $43.6 million, which could represent just a fraction of its potential valuation. With target markets worth more than $11 billion, even a modest market penetration could mean significant value for shareholders. To learn more about Protect Pharma Corp (OTCBB: PRTT), check out the following resources:

Company Website
Latest 10-Q Quarterly Report
Latest 10-K Annual Report

About Protect Pharmaceuticals Corporation
Based in Princeton, New Jersey, Protect (PRTT) is a publicly held drug delivery and new product development company. Protect applies its proprietary drug delivery technologies to develop clinically effective drugs and is building a robust pipeline of product candidates based on its proprietary technologies, scientific knowledge and clinical expertise. For more information, visit www.protectpharm.com.

Safe Harbor Statement
This news release may contain certain forward-looking statements and information concerning Protect’s business, operations, financial condition and prospects. These statements are subject to various risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors. The information set forth herein should be read in light of such risks and uncertainties. The Company assumes no duty or obligation to update these statements at any future date.

Contact
Ram Sesha,CEO,


http://www.pharmaloco.com/company/Protect+Pharmaceuticals,+Inc.+/index.html